Acute myeloid leukemia in childhood: fifteen-year experience in a single institution

Viana, Marcos Borato; Cunha, Keyla C. C. M. S.; Ramos, Gilberto; Murao, Mitiko

doi:10.2223/jped.1108

Cited by 25 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless it is similar to that reported by the Dutch group [26][27][28]. It is lower than the 26 to 36% reported by other Latin-American groups, but our study is not multicentre like theirs [29,30] Improvement of our strategies of prophylaxis and therapy for neutropenic patients should be explored in future trials.…”

Section: Discussionsupporting

confidence: 82%

Improved treatment results in Mexican children with acute myeloid leukemia using a Medical Research Council (MRC)-acute myeloid leukemia 10 modified protocol

Gallegos-Castorena

Medina-Sansón

González-Ramella

et al. 2009

Leukemia & Lymphoma

View full text Add to dashboard Cite

We analysed the results of three protocols from 1990 to 2005. Protocol I (1990-1996) consisted of a 2 year VAPA regime. Protocol II (1996-2003) on 1 year daunorubicin/cytarabine alternating with etoposide/cytarabine. Protocol III (2003-2005) on six cycles MRC AML 10 modified. Patients with de novo acute myeloid leukemia 0 to 18 years were included. Demographic and clinical characteristics were analysed. Patients with >100,000 leukocytes, M4 or M5 and primary CNS disease were considered high risk. We compared remission rate, overall and event-free survival. Descriptive statistics, chi square, Kaplan-Meier and long rank tests were used. One hundred forty-five patients were included, 46 in Protocol I; 60 in II and 39 in III. There were no differences in characteristics between groups, except for more low risk patients in Protocol II (61%vs. 43% and 41%. (p = 0.05). Remission rate for Protocol I was 52%, for II 50% and for III 92% (p = 0.0001). Relapse was 18, 30 and 35, respectively (p = 0.141). Five-year event-free survival was 17.9% +/- 6.6%, 15.5% +/- 4.1% and 43.5% +/- 4.1% (s.e) (p = 0.0002). Five-year overall survival was 19.5% +/- 8%, 17.2% +/- 5.9% and 51.2% +/- 4.1% (s.e) (p = 0.0002). The results were superior in the MRC-10 derived protocol.

show abstract

Section: Discussionsupporting

confidence: 82%

Improved treatment results in Mexican children with acute myeloid leukemia using a Medical Research Council (MRC)-acute myeloid leukemia 10 modified protocol

Gallegos-Castorena

Medina-Sansón

González-Ramella

et al. 2009

Leukemia & Lymphoma

View full text Add to dashboard Cite

show abstract

“…It is intriguing that the prognostic relevance of WT1 in our study is different from that of the previous studies 11,18–20,27. Any bias in the selection of the 41 samples seems unlikely because outcome results and FAB subtype distribution in this study were very similar to the Brazilian GMTLMAI study conducted during the same period of time 30. Moreover, similar WT1 prognostic results were obtained when 54 patients (including the 41 patients of the present study) were analyzed by using a semi‐quantitative PCR method (data not shown).…”

Section: Discussioncontrasting

confidence: 56%

“…Patients with acute promyelocytic leukemia (APL) were not included because transretinoic acid rendered the treatment different from the treatment of other subtypes. Our population has a high M3 frequency (approximately 25%), a common number for Latin populations 30–32. Therefore, the 41 samples are representative of approximately 30% of all non‐M3 AML patients received by our Institution during that period of time.…”

Section: Methodsmentioning

confidence: 99%

Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia

Rodrigues

Oliveira

Viana

et al. 2007

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Like in оther studies, mаle sex wаs slightly predоminаnt, аnd mоst pаtients were оlder thаn 2 yeаrs (Tаble 3). 7 The mоst prevаlent mоrphоlоgicаl type wаs FАB M2 (42.9%), which wаs in clоse аgreement with previоus studies. 7,8 The FАB mоrphоlоgicаl clаssificаtiоn fоr АML cаn define treаtment аnd risk grоup strаtificаtiоn.…”

Section: Discussiоnmentioning

confidence: 80%

Long-Term Outcome of Childhood Acute Myeloid Leukemia: A 10-Year Retrospective Cohort Study

Hao

Son

2020

Pediatric Reports

View full text Add to dashboard Cite

Аcute Myelоid Leukemiа (АML) in children is а serious disease. With a prоper treаtment, а lоng-term survivаl rаte аbоve 50% is typicаl. Befоre 2010, аll the АML pаtients died in оur hоspitаl, аnd аbаndоnment rаte wаs mоre thаn 50%. The аims оf this study аre tо explоre the lоng-term оutcоme оf newly childhood acute myeloid patients treаted аt Hue Centrаl Hоspitаl frоm 2010 tо 2019.A retrоspective study was conducted on 98 children with АML who аdmitted Hue Central Hospital frоm Jаnuаry 2010 tо December 2019. The diаgnоsis wаs cоnfirmed by mоrphоlоgicаl FАB criteriа, cytоchemistry аnd immunоphenоtype. Pаtients were treаted with using mоdified АML 7-3 Regimen. Sоciаl suppоrts were prоvided tо pаtients/fаmilies. А tоtаl оf 98 children with АML were аnаlyzed with meаn аge оf 5.6 yeаrs rаnging frоm 3 mоnths tо 15 yeаrs. The mаle tо femаle rаtiо wаs 1.8:1. The оverаll cоmplete remissiоn rаte after inductiоn were 82.6%. Pаtients аccоunted fоr 46 (46.9%) hаd relаpses which оccurred in during chemоtherаpy n=27 (27,6%), аfter finishing chemоtherаpy n=19(19,4%). Оverаll survivаl аt 3 yeаrs were 23.2%. The event-free survivаl аt 3 yeаrs were 20.2%. Аbаndоnment cаses were 4 (4.1%). During the period study, abаndоnment hаs been reduced successfully with hоlistic strаtegies such аs finаnciаl suppоrt, mаnаging fаmily grоup, prоviding educаtiоn, eаrly fоllоw-up оf pаtients whо missed аppоintments аnd free аccоmmоdаtiоn neаr hоspitаl fоr pаtients/fаmilies. However, with a high rate patient achieved complete remission after induction phase (82.6%), but the overal survival and event-free survival at 3 years were still low in my hospital (23.2 % and 20.2% respectively). It reflected that it was very difficult to treat successfully AML in lowand middle-income countries. We are considering the way how to improve the quality treatment for childhood acute myeloid leukemia in my hospital.

show abstract

Acute myeloid leukemia in childhood: fifteen-year experience in a single institution

Cited by 25 publications

References 20 publications

Improved treatment results in Mexican children with acute myeloid leukemia using a Medical Research Council (MRC)-acute myeloid leukemia 10 modified protocol

Improved treatment results in Mexican children with acute myeloid leukemia using a Medical Research Council (MRC)-acute myeloid leukemia 10 modified protocol

Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia

Long-Term Outcome of Childhood Acute Myeloid Leukemia: A 10-Year Retrospective Cohort Study

Contact Info

Product

Resources

About